304 related articles for article (PubMed ID: 33147518)
1. The interruption of atypical PKC signaling and Temozolomide combination therapy against glioblastoma.
Dey A; Islam SMA; Patel R; Acevedo-Duncan M
Cell Signal; 2021 Jan; 77():109819. PubMed ID: 33147518
[TBL] [Abstract][Full Text] [Related]
2. The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells.
McCray AN; Desai S; Acevedo-Duncan M
Neurochem Res; 2014 Sep; 39(9):1691-701. PubMed ID: 24965532
[TBL] [Abstract][Full Text] [Related]
3. A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma.
Pillai P; Desai S; Patel R; Sajan M; Farese R; Ostrov D; Acevedo-Duncan M
Int J Biochem Cell Biol; 2011 May; 43(5):784-94. PubMed ID: 21315177
[TBL] [Abstract][Full Text] [Related]
4. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
5. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
7. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
8. NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Avci NG; Ebrahimzadeh-Pustchi S; Akay YM; Esquenazi Y; Tandon N; Zhu JJ; Akay M
Sci Rep; 2020 Aug; 10(1):13352. PubMed ID: 32770097
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
11. PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway.
Desai S; Pillai P; Win-Piazza H; Acevedo-Duncan M
Biochim Biophys Acta; 2011 Jun; 1813(6):1190-7. PubMed ID: 21419810
[TBL] [Abstract][Full Text] [Related]
12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
13. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression.
Patel R; Islam SA; Bommareddy RR; Smalley T; Acevedo-Duncan M
Int J Oncol; 2020 Jun; 56(6):1373-1386. PubMed ID: 32236625
[TBL] [Abstract][Full Text] [Related]
15. Regulation of glioblastoma cell invasion by PKC iota and RhoB.
Baldwin RM; Parolin DA; Lorimer IA
Oncogene; 2008 Jun; 27(25):3587-95. PubMed ID: 18212741
[TBL] [Abstract][Full Text] [Related]
16. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Balça-Silva J; Matias D; do Carmo A; Girão H; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC
Biochim Biophys Acta; 2015 Apr; 1850(4):722-32. PubMed ID: 25554223
[TBL] [Abstract][Full Text] [Related]
18. Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Chang HH; Cheng YC; Tsai WC; Tsao MJ; Chen Y
Cell Physiol Biochem; 2018; 48(4):1694-1702. PubMed ID: 30078005
[TBL] [Abstract][Full Text] [Related]
19. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
20. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
